Drug intelligence / Profile preview

Nokifer

Development stage: Unknown
Lead developer: Ronyd Healthcare
Modality: Small Molecules
Administration: Oral

Overview

**Nokifer** is an oral fixed-dose haematinic product marketed by Ronyd Healthcare. Each tablet contains ferrous ascorbate equivalent to 100 mg elemental iron plus folic acid 1.5 mg. It is used to replenish iron and folate and to treat or prevent iron deficiency anemia, including during periods of increased iron requirement such as pregnancy. ([ronydhealthcare.com](https://www.ronydhealthcare.com/Supplements.html))

Brand names: Nokifer

Beyond the preview

Go deeper on Nokifer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nokifer.

Explore the full profile